Spyre Therapeutics (SYRE)

• Market cap: $3.24B
• 1 day: -2.51%
• 5 days: 1.28%
• 1 month: -4.54%
• 3 months: 20.61%
• 6 months: 169.78%
• Year to date: 34.89%
• 1 year: 127.27%
• 5 years: -80.75%
• 10 years: -83.11%
• Sector: Healthcare
• Industry: Biotechnology

About: Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Employees: 102